CEO Anido out at Aerie after Phase II data
Plus: Sage, Gossamer Bio, Nimbus, Inventiva, Selecta and more
A week after Aerie Pharmaceuticals Inc. (NASDAQ:AERI) reported Phase IIb data for dry eye therapy AR-15512 that sent the company’s stock tumbling 26% to $11.59 through Monday’s close, the company has announced the departure of Vicente Anido as chairman and CEO. Benjamin McGraw will serve as interim executive chairman while the company is searching for a new CEO. After hiring of a CEO, Aerie will separate the roles of chairman and CEO. McGraw replaces Vicente Anido, who was previously chairman and CEO. Aerie develops novel treatments for ophthalmic diseases. Aerie gained 6% to $12.27 on Tuesday.
Neurological disorder company Sage Therapeutics Inc. (NASDAQ:SAGE) hired Chris Benecchi as chief commercial officer. Benecchi joins from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) where he was VP and global head of commercial excellence...